热门出版物 - 学术资源搜索

h5 指数:38
h5 中位数:53

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#18 Vascular Medicine

标题/作者	引用次数	年份
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report TA Jacobson, MK Ito, KC Maki, CE Orringer, HE Bays, PH Jones, ... Journal of Clinical Lipidology 9 (2), 129-169	483	2015
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial PM Moriarty, PD Thompson, CP Cannon, JR Guyton, J Bergeron, FJ Zieve, ... Journal of Clinical Lipidology 9 (6), 758-769	331	2015
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 TA Jacobson, KC Maki, CE Orringer, PH Jones, P Kris-Etherton, G Sikand, ... Journal of Clinical Lipidology 9 (6), S1-S122. e1	287	2015
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality RK Wadhera, DL Steen, I Khan, RP Giugliano, JAM Foody Journal of Clinical Lipidology 10 (3), 472-489	188	2016
Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance PD Thompson, J Rubino, MJ Janik, DE MacDougall, SJ McBride, ... Journal of Clinical Lipidology 9 (3), 295-304	85	2015
The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis MCW von Ballmoos, B Haring, FM Sacks Journal of Clinical Lipidology 9 (4), 498-510	80	2015
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association CE Orringer, TA Jacobson, JJ Saseen, AS Brown, AM Gotto, JL Ross, ... Journal of Clinical Lipidology 11 (4), 880-890	78	2017
Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia PB Duell, RD Santos, BA Kirwan, JL Witztum, S Tsimikas, JJP Kastelein Journal of Clinical Lipidology 10 (4), 1011-1021	77	2016
Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs C Stefanutti, U Julius, GF Watts, M Harada-Shiba, M Cossu, VJ Schettler, ... Journal of Clinical Lipidology 11 (4), 858-871. e3	77	2017
Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes A Digenio, R Dunbar, V Alexander, M Hompesch, L Morrow, R Lee, ... Journal of Clinical Lipidology 10 (3), 707-708	73	2016
National Lipid Association Annual Summary of Clinical Lipidology 2016 HE Bays, PH Jones, CE Orringer, WV Brown, TA Jacobson Journal of Clinical Lipidology 10 (1), S1-S43	73	2016
The nocebo effect in the context of statin intolerance JA Tobert, CB Newman Journal of Clinical Lipidology 10 (4), 739-747	69	2016
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance PD Thompson, DE MacDougall, RS Newton, JR Margulies, ... Journal of Clinical Lipidology 10 (3), 556-567	66	2016
Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit J Pang, EB Poulter, DA Bell, TR Bates, VL Jefferson, GS Hillis, CJ Schultz, ... Journal of Clinical Lipidology 9 (5), 703-708	65	2015
The risks of statin use in pregnancy: A systematic review DG Karalis, AN Hill, S Clifton, RA Wild Journal of Clinical Lipidology 10 (5), 1081-1090	64	2016
Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps KC Maki, OM Palacios, M Bell, PP Toth Journal of Clinical Lipidology 11 (5), 1152-1160. e2	59	2017
Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein (a) C Yeang, MY Hung, YS Byun, P Clopton, X Yang, JL Witztum, S Tsimikas Journal of Clinical Lipidology 10 (3), 594-603	59	2016
Efficacy and safety of mipomersen in treatment of dyslipidemia: A meta-analysis of randomized controlled trials R Panta, K Dahal, S Kunwar Journal of Clinical Lipidology 9 (2), 217-225	56	2015
Understanding PCSK9 and anti-PCSK9 therapies JM McKenney Journal of Clinical Lipidology 9 (2), 170-186	54	2015
Use of Lipoprotein (a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association DP Wilson, TA Jacobson, PH Jones, ML Koschinsky, CJ McNeal, ... Journal of Clinical Lipidology 13 (3), 374-392	53	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。